Overview

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.

Phase:

PHASE4

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Capsules
Everolimus
Mycophenolic Acid